drugset / Trial / NCT06983028
Atacicept in Multiple Glomerular Diseases
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
Timeline
- Start
- 2025-07-07
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atacicept | Protein / enzyme biologic | 150 mg | Subcutaneous |